A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Inclusion Criteria: * Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed Consent Form (ICF). * Has epithelial ovarian cancer, inclusive of primary peritoneal or fallopian-tube cancer with a histologically confirmed diagnosis of high grade serous, high grade endometrioid, or clear cell carcinoma, or carcinosarcoma that is resistant to platinum-based therapy. Platinum-resistance is defined as follows: * Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum therapy, must have had a response (CR, PR, stable disease) and then progressed from \>3 months to ≤6 months after the last dose of platinum therapy. * Participants who have received \>1 line of platinum therapy must have progressed on or ≤6 months after the date of the last dose of platinum therapy. • Has received at least 1 but no more than 4 prior lines of systemic anti-cancer therapy. Prior lines of therapy are defined as follows: * Adjuvant ± neoadjuvant are considered one line of therapy. * Maintenance therapy (e.g., bevacizumab, \[poly adenosine diphosphate-ribosylation (ADP) ribose polymerase inhibitor (PARPi)\] will be considered as part of the preceding line of therapy (i.e., not counted independently). * Therapy changed to another agent in the same class due to toxicity in the absence of progression will be considered as part of the same line of therapy (i.…